Actively Recruiting
Open-Label Phase 2 Study Evaluating KP104 in IgA Nephropathy and Complement 3 Glomerulopathy
Led by Kira Pharmacenticals (US), LLC. · Updated on 2026-11-03
52
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying KP104 to evaluate its efficacy, safety, pharmacokinetics, and pharmacodynamics in people with IgA nephropathy IgAN and complement 3 glomerulopathy C3G. This Phase 2 trial will begin with enrolling participants with IgAN to determine the best dose and then include participants with C3G. The study involves two stages focusing on collecting safety, immune response, drug behavior, and effectiveness data. Participants will receive KP104 as subcutaneous injections either weekly or biweekly. Initially, participants with IgAN will be randomized to two dose levels during Stage 1 to identify the optimal biologic dose OBD. Once the OBD is established, participants in Stage 2 with IgAN or C3G will receive KP104 at that dose for a minimum of 47 to 48 weeks. Participants may switch dosing schedules if still in treatment during Stage 1. Throughout the study, participants will be regularly monitored with urine protein and kidney function tests, as well as assessments of drug levels, immune response, and safety events. The primary measurement is the percent change in 24-hour urinary protein creatinine ratio at Week 24 for C3G participants in Stage 2. Adverse events and kidney filtration rates will also be tracked for up to 56 weeks. The total study duration extends to December 2028.
CONDITIONS
Brief Title
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here